Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.

Weiss, L; Melchardt, T; Habringer, S; Boekstegers, A; Hufnagl, C; Neureiter, D; Hopfinger, G; Greil, R; Egle, A; Ann Oncol. 2014; 25(1):171-176

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.

Gnant, M; Filipits, M; Greil, R; Stoeger, H; Rudas, M; Bago-Horvath, Z; Mlineritsch, B; Kwasny, W; Knauer, M; Singer, C; Jakesz, R; Dubsky, P; Fitzal, F; Bartsch, R; Steger, G; Balic, M; Ressler, S; Cowens, JW; Storhoff, J; Ferree, S; Schaper, C; Liu, S; Fesl, C; Nielsen, TO; Ann Oncol. 2014; 25(2): 339-345.

Paraneoplastic Phenomena and Diagnostic Challenges in Angioimmunoblastic T-Cell Lymphoma (AITL): Report of Two Cases and Review of the Literature.

Pircher, A; Verdorfer, I; Brunner, A; Hopfinger, G; Steurer, M; In Vivo. 2014; 28(3): 327-332.

Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells.

Hofbauer, SW; Krenn, PW; Ganghammer, S; Asslaber, D; Pichler, U; Oberascher, K; Henschler, R; Wallner, M; Kerschbaum, H; Greil, R; Hartmann, TN; Blood. 2014; 123(14):2181-2188

Erratum to: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin“s lymphoma (NHL). A multicenter trial by the Austrian Working Group For Medical Tumor Therapy.

Fridrik, MA; Greil, R; Hausmaninger, H; Krieger, O; Oppitz, P; Stöger, M; Klocker, J; Neubauer, M; Helm, W; Pont, J; Fazeny, B; Hudec, M; Simonitsch, I; Radaszkiewicz, T; Ann Hematol. 2014; 93(3): 539-540.

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Ludwig, H; Kasparu, H; Leitgeb, C; Rauch, E; Linkesch, W; Zojer, N; Greil, R; Seebacher, A; Pour, L; Weißmann, A; Adam, Z; Blood. 2014; 123(7):985-991

Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.

Fiegl, M; Stauder, R; Steurer, M; Mian, M; Hopfinger, G; Brychtova, Y; Skrabs, C; Zabernigg, A; Schmid, F; Haslbaur, F; Winder, G; Walder, A; Lang, A; Voskova, D; Greil, R; Mayer, J; Gastl, G; Ann Hematol. 2014; 93(2):26-77

The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia.

Brachtl, G; Piñón Hofbauer, J; Greil, R; Hartmann, TN; Ann Hematol. 2014; 93(3): 361-374.

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Benboubker, L; Dimopoulos, MA; Dispenzieri, A; Catalano, J; Belch, AR; Cavo, M; Pinto, A; Weisel, K; Ludwig, H; Bahlis, N; Banos, A; Tiab, M; Delforge, M; Cavenagh, J; Geraldes, C; Lee, JJ; Chen, C; Oriol, A; de la Rubia, J; Qiu, L; White, DJ; Binder, D; Anderson, K; Fermand, JP; Moreau, P; Attal, M; Knight, R; Chen, G; Van Oostendorp, J; Jacques, C; Ervin-Haynes, A; Avet-Loiseau, H; Hulin, C; Facon, T; N Engl J Med. 2014; 371(10): 906-917.

Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer–a phase II clinical trial.

Eisterer, W; De Vries, A; Öfner, D; Rabl, H; Koplmüller, R; Greil, R; Tschmelitsch, J; Schmid, R; Kapp, K; Lukas, P; Sedlmayer, F; Höfler, G; Gnant, M; Thaler, J; Anticancer Res. 2014; 34(11):676-673